Related Experiment Video
Updated: Aug 11, 2026
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Thrombolytic therapy in the management of acute myocardial infarction
1Department of Medicine, University of Washington School of Medicine.
Insights
Intravenous thrombolytic therapy is the preferred treatment for selected acute myocardial infarction (AMI) patients, especially for first-time, large infarctions within three hours. Careful patient selection is crucial to minimize risks like hemorrhage.
Area of Science:
- Cardiology
- Emergency Medicine
Background:
- Intravenous thrombolytic therapy is a critical intervention for acute myocardial infarction (AMI).
- Optimal timing and patient selection are key for maximizing benefits and minimizing risks.
Purpose of the Study:
- To review the efficacy and safety of intravenous thrombolytic therapy in AMI patients.
- To compare different thrombolytic agents and discuss their role in current clinical practice.
Main Methods:
- Review of current literature on thrombolytic therapy for AMI.
- Analysis of treatment effectiveness based on infarct size, timing, and patient history.
- Discussion of complications and comparative agent efficacy.
Main Results:
- Thrombolytic therapy is most effective for first MIs and large infarctions within 3 hours.
- Benefit is limited after 5-6 hours unless ongoing ischemia is present.
- Careful patient selection is vital to avoid complications like intracerebral hemorrhage.
Conclusions:
- Intravenous thrombolytic therapy is the treatment of choice for selected AMI patients.
- Recombinant tissue plasminogen activator (rt-PA) may be preferable to streptokinase, pending further data.
- Cost-effectiveness and clinical outcomes will guide future use of thrombolytic agents.
Abstract:
It is now clear that intravenous thrombolytic therapy is the treatment of choice in selected patients with AMI. It is most effective in patients with their first MIs and of greatest benefit, at least in the short term, for those with large infarctions. It should be given within the first three hours to be most effective and there probably is little benefit for patients after 5-6 hours unless there is evidence of ongoing ischemia. Patients must be selected carefully to reduce the likelihood of serious complications, including intracerebral hemorrhage. There is, as yet, no convincing evidence that early intervention with PTCA or surgery can improve the outcome of patients who have received initial early intravenous thrombolytic therapy when they develop recurrent myocardial ischemia (21,22). The use of rt-PA probably is preferable to the use of streptokinase, but further experience is needed before this can be determined with certainty. The large difference in the cost of these agents will need to be evaluated by the medical community and other health care providers who finally will determine the pattern of use of these and future thrombolytic agents.
Related Concept Videos
01:14Myocarditis III: Medical Management
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care